Zhongguo Fei Ai Za Zhi. 2020 Jul 20;23(7):626-630. doi: 10.3779/j.issn.1009-3419.2020.101.34.
As the first anti-angiogenesis monoclonal antibody, bevacizumab has been an vital component of front line regimen of advanced nonsqaumous non-small cell lung cancer (NSCLC). It increase the efficacy of chemotherapy, epithelial growth factor receptor tyrosine kinase inhibitors and immune checkpoint inhibitors. This article is an important review of existing randomized controlled clinical research, hoping to provide a reference for clinical treatment. The addition of bevacizumab reduces the risk
of disease progression in patients with advanced non-squamous NSCLC significantly. Specific combinations can also reduce the risk of death. The best combination plan needs to be confirmed by new randomized controlled studies.